Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
Giuseppe Derosa,1–3 Pamela Maffioli1 1Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Centre for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-09-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/ertugliflozin-a-sodium-glucose-cotransporter-2-sglt-2-inhibitor-for-gl-peer-reviewed-article-TCRM |